SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SignaBlok > News

SignaBlok > News

SignaBlok to present preclinical data on TREM-1-targeting drug for the treatment of cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SignaBlok released PHS-Financial Conflict of Interest (FCOI) Policy

SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale

Sigalov AB. Biochimie. 2022

SignaBlok presented preclinical data on the use of ligand-independent TREM-1 blockers as innate immune checkpoint inhibitors to overcome cancer immunotherapy resistance at the CICON23

SignaBlok awarded NEI / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitors for neovascular retinal diseases

SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome

Triggering receptor expressed on myeloid cells-1 (TREM-1) contributes to Bordetella pertussis inflammatory pathology

Gallop D, Scanlon K et al. Infect Immun. 2021

SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.

SignaBlok awarded NIAMS / NIH SBIR Phase I grant to test new approach to treatment of scleroderma

SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis